Earnings call Verrica reported Q3 2025 revenue of $14.3M, up from a negative $1.8M in Q3 2024, driven by $10.7M in Torii milestone revenue and $3.6M in YCANTH sales. YCANTH dispensed units rose 120% ...

Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' Third Quarter 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being ...

Total Revenue: $14.3 million for Q3 2025, compared to negative $1.8 million in Q3 2024. Torii Milestone and Collaboration Revenue: $10.7 million in Q3 2025. Net YCANTH Revenue: $3.6 million in Q3 2025 ...

Verrica Pharmaceuticals VRCA is preparing to release its quarterly earnings on Tuesday, 2025-08-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

We all download a vast number of files on our devices every day. Many of the files we download can get lost in our vast list of downloads. In such a scenario, having a file open automatically upon ...

“A nation that is afraid to let its people judge the truth and falsehood in an open market is a nation that is afraid of its people.” – John F. Kennedy On November 22, 1963, crowds of excited people ...

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript March 11, 2025 Verrica Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.24, expectations were $-0.25.

In a report released today, Serge Belanger from Needham maintained a Hold rating on Verrica Pharmaceuticals (VRCA – Research Report). The company’s shares closed yesterday at $0.65. Effectively assess ...

Fintel reports that on November 5, 2024, RBC Capital downgraded their outlook for Verrica Pharmaceuticals (NasdaqGM:VRCA) from Outperform to Sector Perform. Analyst Price Forecast Suggests 1,550.90% ...